| 2026-04-29 |
财报披露：
美东时间 2026-04-29 盘后发布财报
|
| 2026-02-15 |
详情>>
内部人交易：
Baumgartner Florian等共交易16笔
|
| 2026-01-29 |
详情>>
股本变动：
变动后总股本2428.52万股
|
| 2026-01-29 |
详情>>
业绩披露：
2026年中报每股收益2.32美元,归母净利润5698.10万美元,同比去年增长17.47%
|
| 2025-10-30 |
详情>>
业绩披露：
2026年一季报每股收益0.31美元,归母净利润763.70万美元,同比去年增长160.86%
|
| 2025-10-28 |
股东大会：
将于2025-12-17召开股东大会
会议内容 ▼▲
- 1.Reappoint Robert S. Keane to our Board of Directors to serve for a term of three years ending at the conclusion of our annual general meeting of shareholders in 2028
2.Reappoint Scott J. Vassalluzzo to our Board of Directors to serve for a term of three years ending at the conclusion of our annual general meeting of shareholders in 2028
3.Approve, on a non-binding, advisory basis, the compensation of our named executive officers, as described in this proxy statement
4.Renew the authority of our Board of Directors, until June 17, 2027, to issue authorized but unissued ordinary shares of Cimpress plc up to a maximum of 20% of our issued and outstanding share capital
5.Renew the authority of our Board of Directors, until June 17, 2027, to opt out of statutory preemption rights under Irish law with respect to the issuance of ordinary shares for cash, up to a maximum of 20% of our issued and outstanding share capital
6.Reappoint PricewaterhouseCoopers Ireland as our statutory auditor under Irish law to hold office until the conclusion of our annual general meeting of shareholders in 2026
7.Authorize our Board of Directors or Audit Committee to determine the remuneration of PricewaterhouseCoopers Ireland in its capacity as our statutory auditor under Irish law
8.Transact other business, if any, that may properly come before the meeting or any adjournment of the meeting
|
| 2025-08-08 |
详情>>
业绩披露：
2023年年报每股收益-7.08美元,归母净利润-1.86亿美元,同比去年增长-242.31%
|
| 2025-08-08 |
详情>>
业绩披露：
2025年年报每股收益0.60美元,归母净利润1495.20万美元,同比去年增长-91.39%
|
| 2025-05-02 |
详情>>
业绩披露：
2025年三季报(累计)每股收益1.61美元,归母净利润4027.00万美元,同比去年增长-31.37%
|
| 2025-01-31 |
详情>>
业绩披露：
2025年中报每股收益1.94美元,归母净利润4850.80万美元,同比去年增长-22.58%
|
| 2024-10-31 |
详情>>
业绩披露：
2025年一季报每股收益-0.5美元,归母净利润-1254.9万美元,同比去年增长-375.56%
|
| 2024-10-31 |
详情>>
业绩披露：
2024年一季报每股收益0.17美元,归母净利润455.40万美元,同比去年增长117.90%
|
| 2024-10-09 |
股东大会：
将于2024-11-20召开股东大会
会议内容 ▼▲
- 1.Reappoint Dessislava Temperley to our Board of Directors to serve for a term of three years ending at the conclusion of our annual general meeting of shareholders in 2027
2.Approve, on a non-binding, advisory basis, the compensation of our named executive officers, as described in this proxy statement
3.Amend our 2020 Equity Incentive Plan to increase the number of ordinary shares issuable under the plan by 2,000,000 shares
4.Renew the authority of our Board of Directors, until May 20, 2026, to issue authorized but unissued ordinary shares of Cimpress plc up to a maximum of 20% of our issued and outstanding share capital
5.Renew the authority of our Board of Directors, until May 20, 2026, to opt out of statutory preemption rights under Irish law with respect to the issuance of ordinary shares for cash, up to a maximum of 20% of our issued and outstanding share capital
6.Reappoint PricewaterhouseCoopers Ireland as our statutory auditor under Irish law to hold office until the conclusion of our annual general meeting of shareholders in 2025
7.Authorize our Board of Directors or Audit Committee to determine the remuneration of PricewaterhouseCoopers Ireland in its capacity as our statutory auditor under Irish law
8.Transact other business, if any, that may properly come before the meeting or any adjournment of the meeting
|
| 2024-08-09 |
详情>>
业绩披露：
2024年年报每股收益6.64美元,归母净利润1.74亿美元,同比去年增长193.39%
|
| 2024-05-02 |
详情>>
业绩披露：
2024年三季报(累计)每股收益2.22美元,归母净利润5868.10万美元,同比去年增长127.32%
|
| 2024-02-01 |
详情>>
业绩披露：
2024年中报每股收益2.36美元,归母净利润6265.90万美元,同比去年增长137.87%
|
| 2023-10-26 |
股东大会：
将于2023-12-14召开股东大会
会议内容 ▼▲
- 1.Reappoint Sophie A. Gasperment to our Board of Directors to serve for a term of three years ending at the conclusion of our annual general meeting of shareholders in 2026
2.Approve, on a non-binding, advisory basis, the compensation of our named executive officers, as described in this proxy statement
3.Renew the authority of our Board of Directors, until June 14, 2025, to issue authorized but unissued ordinary shares of Cimpress plc up to a maximum of 20% of our issued share capital
4.Renew the authority of our Board of Directors, until June 14, 2025, to opt out of statutory preemption rights under Irish law with respect to the issuance of ordinary shares for cash, up to a maximum of 20% of our issued share capital
5.Reappoint PricewaterhouseCoopers Ireland as our statutory auditor under Irish law to hold office until the conclusion of our annual general meeting of shareholders in 2024
6.Authorize our Board of Directors or Audit Committee to determine the remuneration of PricewaterhouseCoopers Ireland in its capacity as our statutory auditor under Irish law
7.Hold a non-binding, advisory "say on frequency" vote regarding the frequency of the future advisory votes on executive compensation (once every year, every two years, or every three years)
8.Transact other business, if any, that may properly come before the meeting or any adjournment of the meeting
|
| 2022-10-05 |
股东大会：
将于2022-11-16召开股东大会
会议内容 ▼▲
- 1.Reappoint Robert S. Keane to our Board of Directors to serve for a term of three years ending at the conclusion of our annual general meeting of shareholders in 2025
2.Reappoint Scott J. Vassalluzzo to our Board of Directors to serve for a term of three years ending at the conclusion of our annual general meeting of shareholders in 2025
3.Approve, on a non-binding, advisory basis, the compensation of our named executive officers, as described in this proxy statement
4.Amend our 2020 Equity Incentive Plan to increase the number of ordinary shares issuable under the plan by 2,000,000 shares
5.Reappoint PricewaterhouseCoopers Ireland as our statutory auditor under Irish law to hold office until the conclusion of our annual general meeting of shareholders in 2023
6.Authorize our Board of Directors or Audit Committee to determine the remuneration of PricewaterhouseCoopers Ireland in its capacity as our statutory auditor under Irish law
7.Transact other business, if any, that may properly come before the meeting or any adjournment of the meeting
|
| 2021-10-19 |
股东大会：
将于2021-11-30召开股东大会
会议内容 ▼▲
- 1.Reappoint Zachary S. Sternberg to our Board of Directors to serve for a term of three years ending at the conclusion of our annual general meeting of shareholders in 2024
2.Approve, on a non-binding, advisory basis, the compensation of our named executive officers, as described in this proxy statement
3.Set the minimum price at which we may reissue our treasury shares at $0 and the maximum price at which we may reissue our treasury shares at an amount equal to 200% of the market price of our ordinary shares on the Nasdaq Global Select Market, or Nasdaq, or any other securities exchange where our shares are then traded, until May 30, 2023
4.Reappoint PricewaterhouseCoopers Ireland as our statutory auditor under Irish law to hold office until the conclusion of our annual general meeting of shareholders in 2022
5.Authorize our Board of Directors or Audit Committee to determine the remuneration of PricewaterhouseCoopers Ireland in its capacity as our statutory auditor under Irish law
6.Transact other business, if any, that may properly come before the meeting or any adjournment of the meeting
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2020-10-07 |
股东大会：
将于2020-11-25召开股东大会
会议内容 ▼▲
- 1.Reappoint Sophie A. Gasperment to our Board of Directors to serve for a term of three years ending at the conclusion of our annual general meeting of shareholders in 2023
2.Approve, on a non-binding, advisory basis, the compensation of our named executive officers, as described in this proxy statement
3.Approve our proposed 2020 Equity Incentive Plan
4.Set the minimum price at which we may reissue our treasury shares at 0.01Euro and the maximum price at which we may reissue our treasury shares at an amount equal to 200% of the market price of our ordinary shares on the Nasdaq Global Select Market, or Nasdaq, or any other securities exchange where our shares are then traded, until May 25, 2022
5.Reappoint PricewaterhouseCoopers Ireland as our statutory auditor under Irish law to hold office until the conclusion of our annual general meeting of shareholders in 2021
6.Authorize our Board of Directors or Audit Committee to determine the remuneration of PricewaterhouseCoopers Ireland in its capacity as our statutory auditor under Irish law
7.Transact other business, if any, that may properly come before the meeting or any adjournment of the meeting
|
| 2019-10-28 |
股东大会：
将于2019-11-22召开股东大会
会议内容 ▼▲
- 1.Appoint Robert S. Keane as an executive director to our Board of Directors to serve for a term of three years ending on the date of our annual general meeting of shareholders in 2022
2.approve an amendment to IZEA’s 2011 Equity Incentive Plan.
3.approve on a non-binding advisory basis, the compensation paid to IZEA’s named executive officers (commonly known as “say-on-pay”);
4.ratify the appointment of BDO USA, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019;
5.transact such other business as may properly come before the Annual Meeting and any adjournents or postponements thereof.
|
| 2018-10-22 |
股东大会：
将于2018-11-13召开股东大会
会议内容 ▼▲
- 1.Approve the amendment and restatement of our articles of association to replace our current two-tier board structure (consisting of a Supervisory Board and a separate Management Board) with a single-tier Board of Directors
2.Appoint Robert S. Keane as an executive director to our Board of Directors to serve for a term of one year ending on the date of our annual general meeting of shareholders in 2019
3.Appoint Scott Vassalluzzo as a non-executive director to our Board of Directors to serve for a term of one year ending on the date of our annual general meeting of shareholders in 2019
4.Appoint Sophie A. Gasperment as a non-executive director to our Board of Directors to serve for a term of two years ending on the date of our annual general meeting of shareholders in 2020
5.Appoint John J. Gavin, Jr. as a non-executive director to our Board of Directors to serve for a term of three years ending on the date of our annual general meeting of shareholders in 2021
6.Appoint Zachary S. Sternberg as a non-executive director to our Board of Directors to serve for a term of three years ending on the date of our annual general meeting of shareholders in 2021
7.Following a discussion on the application of the remuneration policy over the fiscal year ended June 30, 2018, hold a non-binding, advisory “say on pay” vote regarding the compensation of our named executive officers, as described in the Compensation Discussion and Analysis, executive compensation tables, and accompanying narrative disclosures in this proxy statement
8.Adopt our statutory annual accounts, as prepared in accordance with Dutch law, for the fiscal year ended June 30, 2018
9.Discharge the members of our Management Board from liability with respect to the exercise of their duties during the fiscal year ended June 30, 2018
10.Discharge the members of our Supervisory Board from liability with respect to the exercise of their duties during the fiscal year ended June 30, 2018
11.Authorize our Board of Directors until May 13, 2020 to repurchase up to 6,200,000 of our issued and outstanding ordinary shares (which represents approximately 20% of our 30.9 million shares outstanding as of June 30, 2018) on the open market (including block trades that satisfy the safe harbor provisions of Rule 10b-18 pursuant to the United States Securities Exchange Act of 1934, or the Exchange Act), through privately negotiated transactions, or in one or more self-tender offers at prices per share between 0.01 and an amount equal to 120% of the market price of our ordinary shares on the Nasdaq Global Select Market, or Nasdaq, or any other securities exchange where our shares are then traded (the market price being deemed to be the average of the closing price on each of the consecutive days of trading during a period no shorter than one trading day and no longer than 10 trading days immediately preceding the date of repurchase, as reasonably determined by the Board of Directors)
12.Authorize our Board of Directors until May 13, 2020 to issue ordinary shares or grant rights to subscribe for ordinary shares up to a maximum of (i) 10% of our outstanding share capital at the time of issue for general corporate purposes including but not limited to equity compensation, acquisitions, and financings, and (ii) an additional 10% of our outstanding share capital at the time of issue in connection with our acquisition of all or a majority of the equity or assets of another entity
13.Authorize our Board of Directors until May 13, 2020 to resolve to exclude or restrict our shareholders’ preemptive rights under Dutch law with respect to ordinary shares and rights to subscribe for ordinary shares that the Board of Directors may issue or grant pursuant to any authorization of our shareholders
14.Appoint PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending June 30, 2019
15.Approve a remuneration policy for our Board of Directors
16.Approve the grant of ordinary share awards as severance to the members of our Supervisory Board who were not nominated for appointment to our Board of Directors
17.Approve an amendment to our 2016 Performance Equity Plan
18.Transact other business, if any, that may properly come before the meeting or any adjournment of the meeting
|
| 2018-03-30 |
股东大会：
将于2018-04-25召开股东大会
会议内容 ▼▲
- (1) Approve a first amendment to article 4.1 of our articles of association to increase our authorized capital from EUR 2,000,000 to EUR 3,858,000,000 and increase the nominal value of each ordinary share and each preferred share from EUR 0.01 to EUR 19.29;
(2) Approve a second amendment to article 4.1 of our articles of association to decrease our authorized capital from EUR 3,858,000,000 to EUR 2,000,000 and decrease the nominal value of each ordinary share and each preferred share from EUR 19.29 to EUR 0.01;
(3) Transact other business, if any, that may properly come before the meeting or any adjournment of the meeting.
|
| 2017-10-23 |
股东大会：
将于2017-11-14召开股东大会
会议内容 ▼▲
- 1. Reappoint John J. Gavin, Jr. to our Supervisory Board to serve for a term of four years ending on the date of our annual general meeting of shareholders in 2021;
2.Appoint Zachary S. Sternberg to our Supervisory Board to serve for a term of four years ending on the date of our annual general meeting of shareholders in 2021;
3.Reappoint Robert S. Keane to our Management Board to serve for a term of four years ending on the date of our annual general meeting of shareholders in 2021;
4.Appoint Sean E. Quinn to our Management Board to serve for a term of three years ending on the date of our annual general meeting of shareholders in 2020;
5.Following a discussion on the application of the remuneration policy over the fiscal year ended June 30, 2017, hold a non-binding, advisory “say on pay” vote regarding the compensation of our named executive officers, as described in the Compensation Discussion and Analysis, executive compensation tables, and accompanying narrative disclosures in this proxy statement;
6.Adopt our statutory annual accounts, as prepared in accordance with Dutch law, for the fiscal year ended June 30, 2017;
7.Discharge the members of our Management Board from liability with respect to the exercise of their duties during the fiscal year ended June 30, 2017;
8.Discharge the members of our Supervisory Board from liability with respect to the exercise of their duties during the fiscal year ended June 30, 2017;
9.Authorize our Management Board, acting with the approval of our Supervisory Board, until May 14, 2019 to repurchase up to 6,300,000 of our issued and outstanding ordinary shares (which represents approximately 20% of our 31.4 million shares outstanding as of June 30, 2017) on the open market (including block trades that satisfy the safe harbor provisions of Rule 10b-18 pursuant to the United States Securities Exchange Act of 1934, or the Exchange Act), through privately negotiated transactions, or in one or more self-tender offers at prices per share between an amount equal to 0.01 and an amount equal to 120% of the market price of our ordinary shares on the Nasdaq Global Select Market, or Nasdaq, or any other securities exchange where our shares are then traded (the market price being deemed to be the avrage of the closing price on each of the consecutive days of trading during a period no shorter than one trading day and no longer than 10 trading days immediately preceding the date of repurchase, as reasonably determined by the Management Board);
10.Renew the authorization of our Management Board, acting with the approval of our Supervisory Board, until May 14, 2019 to issue ordinary shares or grant rights to subscribe for ordinary shares up to a maximum of (i) 10% of our outstanding share capital at the time of issue for general corporate purposes including but not limited to equity compensation, acquisitions, and financings, and (ii) an additional 10% of our outstanding share capital at the time of issue in connection with our acquisition of all or a majority of the equity or assets of another entity;
11.Renew the authorization of our Management Board, acting with the approval of our Supervisory Board, until May 14, 2019 to resolve to exclude or restrict our shareholders’ preemptive rights under Dutch law with respect to ordinary shares and rights to subscribe for ordinary shares that the Management Board may issue or grant pursuant to any authorization of our shareholders;
12.Appoint PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending June 30, 2018;
13.Hold a non-binding, advisory “say on frequency” vote regarding the frequency of the future advisory votes on executive compensation (once every year, every two years or every three years);
14.Transact other business, if any, that may properly come before the meeting or any adjournment of the meeting.
|
| 2016-10-24 |
股东大会：
将于2016-11-15召开股东大会
会议内容 ▼▲
- 1. Reappoint Paolo De Cesare to our Supervisory Board to serve for a term of four years ending on the date of our annual general meeting of shareholders in 2020;
2. Reappoint Mark T. Thomas to our Supervisory Board to serve for a term of four years ending on the date of our annual general meeting of shareholders in 2020;
3. Appoint Sophie A. Gasperment to our Supervisory Board to serve for a term of four years ending on the date of our annual general meeting of shareholders in 2020;
4. Following a discussion on the application of the remuneration policy over the fiscal year ended June 30, 2016, hold a non-binding, advisory “say on pay” vote regarding the compensation of our named executive officers, as described in the Compensation Discussion and Analysis, executive compensation tables, and accompanying narrative disclosures in this proxy statement;
5. Adopt our statutory annual accounts, as prepared in accordance with Dutch law, for the fiscal year ended June 30, 2016;
6. Discharge the members of our Management Board from liability with respect to the exercise of their duties during the fiscal year ended June 30, 2016;
7. Discharge the members of our Supervisory Board from liability with respect to the exercise of their duties during the fiscal year ended June 30, 2016;
8. Authorize our Management Board, acting with the approval of our Supervisory Board, to repurchase up to 6,300,000 of our issued and outstanding ordinary shares (which represents approximately 20% of our 31.5 million shares outstanding as of June 30, 2016) until May 15, 2018 on the open market (including block trades that satisfy the safe harbor provisions of Rule 10b-18 pursuant to the United States Securities Exchange Act of 1934, or the Exchange Act), through privately negotiated transactions, or in one or more self-tender offers at prices per share between an amount equal to 0.01 and an amount equal to 120% of the market price of our ordinary shares on the Nasdaq Global Select Market, or Nasdaq, or any other securities exchange where our shares are then traded (the market price being deemed to be the average of the closing price on each of the consecutive days of trading during a period no shorter than one trading day and no longer than 10 trading days immediately preceding the date of repurchase, as reasonably determined by the Management Board);
9. Renew the authorization of our Management Board, acting with the approval of our Supervisory Board, until May 15, 2018 to issue ordinary shares or grant rights to subscribe for ordinary shares up to a maximum of (i) 10% of our outstanding share capital at the time of issue for general corporate purposes including but not limited to equity compensation, acquisitions, and financings, and (ii) an additional 10% of our outstanding share capital at the time of issue in connection with our acquisition of all or a majority of the equity or assets of another entity;
10. Renew the authorization of our Management Board, acting with the approval of our Supervisory Board, until May 15, 2018 to resolve to exclude or restrict our shareholders’ preemptive rights under Dutch law with respect to ordinary shares and rights to subscribe for ordinary shares that the Management Board may issue or grant pursuant to any authorization of our shareholders;
11. Appoint PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending June 30, 2017;
12. Approve the new compensation program for our Supervisory Board described in this proxy statement;
13. Approve the amendment to our 2016 Performance Equity Plan described in this proxy statement;
14. Transact other business, if any, that may properly come before the meeting or any adjournment of the meeting.
|
| 2016-05-04 |
股东大会：
将于2016-05-27召开股东大会
会议内容 ▼▲
- 1.Approve our 2016 Performance Equity Plan;
2.Amend the Remuneration Policy applicable to our Management Board to allow our Supervisory Board to grant performance awards under the 2016 Performance Equity Plan to the members of our Management Board;
3.Authorize our Management Board, acting with the approval of our Supervisory Board, until May 27, 2021, to issue ordinary shares or grant rights to subscribe for ordinary shares pursuant to our 2016 Performance Equity Plan;
4.Transact other business, if any, that may properly come before the meeting or any adjournment of the meeting.
|
| 2013-02-01 |
复牌提示：
2013-01-31 16:00:14 停牌，复牌日期 2013-01-31 16:35:00
|